Cytomedix Inc.'s AutoloGel Featured at Native American Wound Care Conference and Diabetic Limb Salvage Conference
Published: Oct 12, 2012
GAITHERSBURG, MD--(Marketwire - October 11, 2012) - Cytomedix, Inc. (OTCQX: CMXI) (the "Company"), a leading developer of biologically active regenerative therapies, today announced that its AutoloGel system is featured at two medical conferences this week, the Inaugural Native American Wound Care Conference in Cabazon, CA, and the Diabetic Limb Salvage Conference in Washington D.C.
The AutoloGel System, a device for the production of autologous platelet rich plasma ("PRP") gel, is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use in wound management.
Native American Wound Care Conference
Morongo Casino Resort & Spa, Cabazon, CA, Oct 8 - 9.
- Dr. Laurie Rappl of Cytomedix hosted a discussion of AutoloGel platelet rich plasma (PRP) and the outcomes achieved using a physiologic concentration PRP Gel in chronic wounds of all etiologies. Dr. Rappl demonstrated how to make and apply AutoloGel to a wound. The lecture covered indications, contraindications, appropriate care after application, and expected outcomes including cost comparison scenarios vs.tissue grafting and NPWT.
The Native American Wound Care Conference was developed to address the higher rates of wound-related complications, amputations and diabetes. Approximately 60% of Native Americans die within two years after an amputation caused by inadequately treated wounds. Tribal Representatives and health care professionals will discuss a range of topics including prevention, diagnosis and treatment of wounds; financing, design and construction of wound care facilities; and the importance of lifestyle, traditional medicine, and awareness within the Tribal community.
Diabetic Limb Salvage Conference
JW Marriott, Washington, D.C. Oct 11 - 13.
- Healing Wagner III and IV Wounds Complicated by Arterial Disease Using Platelet-Rich-Plasma Gel: This study was designed to look at evidence-based treatment outcomes in 39 Japanese patients with 40 complex and severe ulcerations in wound care centers who were treated with AutoloGel. The results showed that 83% of severe, complex wounds, including Wagner III and IV wounds in patients with diabetes and moderate to severe arteriosclerotic obliterans (ASO), healed completely. The lead investigator was Dr. Chugo Rinoie, DPM, ABPO, CWS, Chief of Podiatric Surgery, Wound Healing Center, Methodist Hospital of Southern California, Arcadia, California.
Dr. Rinoie, who was attending the meeting, commented, "The results in these patients are very encouraging. This is a complex and very difficult to treat patient population with poor healing prognosis and a high risk of lower extremity amputation (LEA). The use of AutoloGel represents a meaningful improvement in the standard of care."
The Diabetic Limb Salvage Conference provides medical practitioners with the opportunity to learn about the latest research and the most advanced therapies in this field. The meeting format includes didactic lectures, hands-on workshops, specialty symposia, and live surgical case demonstrations for the purpose of providing a live interactive learning experience. More than 60 distinguished faculty members are presenting and approximately 1,200 delegates are expected to attend.
About Cytomedix, Inc.
Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel™ System, cleared by the FDA for wound care and the Angel® Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDHbr") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit www.cytomedix.com.
Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.
Chief Executive Officer
Chief Financial Officer